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Fig. 5. Flow diagram of purim, thymidine and pro- 
rein synthesis. 
problems presented and the management of 
research show important differences, it is 
essential that industry continues to recruit 
its proper proportion of the available talent. 
Medawar has commented that the ordi- 
nary processes of scientific discovery are 
slow, messy and uneconomic and cannot be 
premeditated. Industry is recognizing that 
‘creativity and ultimate rewards are sup 
ported by the greatest achievable sophisti- 
cation and fostered by a very tolerant defini- 
tion of relevance’ (Hitchings). 
JULIAN H. SHELLEY 
Boehringer lngelheim, Southern Industrial Estate, 
Bracknell, Berkshire, UK. 
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The joint French-US seminar on 
phencyclidine and related 
arylcyclohexylamines 
A joint French-US seminar was held at La 
Grande Motte (Montpellier) France, 20-24 
September 1982, to assess the current sci- 
entific status of phencyclidine (PCP) and 
related arylcyclohexylamines. The seminar 
was attended by 58 scientists interested in 
the chemistry, biochemistry, pharmacol- 
ogy, therapeutic applications and drug 
abuse aspects of arylcyclohexylamines. 
Thirty-four American, 19 French, 3 Japan 
ese, 1 British and 1 Israeli investigator 
attended, representing each of the above 
major disciplines. The organizing commit- 
tee consisted of E. F. Domino of the Uni- 
versity of Michigan and P. Geneste and 
J. M. Kamenka of the Universite de Mont- 
pellier, Ecole Nationale Sup&ieure de 
Chimie. 
The medicinal chemical aspects were 
described first. It was shown that many dif- 
ferent arylcyclohexylamines possess PCP- 
like properties which overlap with the 
opioid narcotics. The active conformation 
of PCP was described by Kamenka and 
Geneste (Montpellier). Its chameleon-like 
property of changing the aryl group from 
axial to equatorial to the cyclohexyl ring 
with protonated and non-protonated 
molecular species, suggests the complexity 
of determining its active form. This was 
accomplished by studying the effects of 
more thermodynamicahy stable com- 
pounds. It was suggested that the biologi- 
cally active conformation of PCP requires 
an axial phenyl group in the complex ligand 
receptor. In addition, preferred solution 
conformations, similar to that of PCP 
hydrochloride, were found for a series of 
atylcyclohexylamine hydrochlotides by 
Brine and associates (Research Triangle 
Institute). Lednicer (Adria) and P. F. Von 
Voigtlander (Upjohn) described the 
chemistry and structure-activity relation- 
ships of a series of 4-aminc&arylcyclo- 
hexanols. The presence of an oxygen 
function on the cyclohexane ring produces 
compounds that are narcotic opioids, both 
pure pagonists and mixed pagonists 
antagonists, as well as pure kantagonists. 
The bromo, phenethyl derivative (U 48843) 
has 12 300 times the potency of morphine 
as an analgesic of the ktype. This makes 
this compound, 4-@ bromophenyl&4- 
(dimethylamino) - 1 - phenethylcyclohexanol 
(tram OH/N) one of the most potent opioid 
analgesics known. Removal of the oxygen 
group in this series produces compounds 
with PCP-like activity to varying degrees. 
Zimmerman and associates (Lilly) reported 
the discovery and characterization of a new 
series of benzo(f)isoquinoline derivatives 
that have stimulus discriminative properties 
similar to PCP. One of the most potent is 
the methylcyclopropyl bridged iso 
quinoline, LY 154045. PCP-like effects 
were maximized with a hydroxyl sub 
stituent in the aromatic ring. 
One of the major questions in PCP 
research today is whether there is a PCP 
receptor. Lazdunski, Vincent and col- 
leagues (Nice) reviewed the properties 
required for a PCP binding site to be called 
a PCP receptor. These include: (1) 
specific, reversible and saturable binding; 
(2) a specific correlation between affinity 
and biological activity such as PCP 
stimulus discrimination, mouse rotarod 
behavior etc. ; (3) no displacement of bind- 
ing by molecules with a different phar- 
macological action; (4) the KD of binding 
must be in the concentration range for 
relevant pharmacological actions; (5) there 
must be stereospecificity; (6) tissue re 
gional distribution of binding must be con- 
sistent with known pharmacological 
actions; (7) a specific antagonist of the 
pharmacological effects of PCP must pre- 
vent its binding. 
In the case of PCP, most of these criteria, 
except that of a specific antagonist prevent- 
ing binding, have been met. Lazdunski 
pointed out the maximum binding capacity 
of PCP of more than 2 pm01 mg-’ protein. 
This is a very large amount of binding as 
compared with the binding capacities for 
most neurotransmitters. Pronase, trypsin 
and papain treatment destroys PCP bind- 
ing, but phospholipases do not. This, and 
the stereospecificity of the binding, show 
that the receptor is a protein. High Na+ 
concentration blocks PCP binding, as do 
local anesthetics and histrionicotoxin. PCP 
also acts on the muscarinic cholinergic 
receptor, but at high concentrations near 30 
PM. In embryonic chick cardiac cells in cul- 
ture, PCP produces a negative inotropic 
effect just like acetylcholine (ACh). In 
neuroblastoma cells in culture PCP blocks 
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the Na+-channel and the K+-channel. The 
K+-channel is completely blocked when 
PCP reduces the Na+-channel activity by 
50%, causing a reduced, but prolonged 
action potential. The Ca’+-dependent 
K+-channel and the slow Caz+-charmel are 
not affected. PCP also blocks dopamine 
(DA) uptake in concentrations which are 
the same as those found for the saturation of 
the PCP receptor with [SHIPCP. From a 
structure-activity point of view, metu 
OH-PCP (a potential PCP metabolite) is the 
most potent of the compounds studied; it is 
also very potent in its affinity for opiate 
receptors. 
S. R. Zukin (Albert Einstein College) 
reviewed recent progress in PCP receptor 
research. He further characterized its kin- 
etic association and dissociation rate con- 
stants as 2.9 x loshl-’ and 4.8 x 
10-l min-‘, yielding a KD of 1.6 x ~O+M 
in agreement with previous data. The per- 
missible separation time of 13 s was well 
above the 10 s of the rapid filtration assay. 
Precoating the filters with 0.01% poly-L 
lysine or 0.05% polyethyleneimine elimi- 
nated any displaceable [sH]PCP binding to 
GF/B filters. Stereospecificity for the PCP 
receptor was demonstrated in that (+ b 
ketamine was four times more potent than 
(-~ketamine, and dexoxadrol was 100 
times more potent than levoxadrol. Pro 
teolytic enzymes, including trypsin, papain 
and thermolysin, inactivated stereospecitic 
and overall specific PCP binding. The sub 
icular cortex and hippocampus showed the 
greatest PCP binding, with intermediate 
levels in the frontal cortex, hypothalamus, 
cerebellum and striatum. Negligible levels 
of PCP binding were found in the white 
matter of the corpus callosum. 
R. S. Zukin (Albert Einstein College) 
reviewed the biochemical evidence for a 
common PCP/cr opiate receptor. She 
stressed that it is not an opiate receptor, but 
rather a unique and distinctive receptor. 
According to this concept, Zajac, 
Roques and colleagues (Universite Rene 
Descartes) showed that highly selective 
synthetic peptides with brain CL_ and 
&opiate receptor agonist actions did not 
interact with PCP binding sites. Indeed, 
these agonists exhibited low inhibitory 
potency (I& 10 000 no) on [3H]PCP 
binding in rat brain. g-selective agonists 
increased [3H]DA release in vivo after 
intracerebroventricular injection in caudate 
nucleus of cats and in vitro in rat striatal 
slices. This effect, which is not antagonized 
by naloxone, was obtained at low doses and 
may be related to the behavioral effects of 
opiates. Interestingly, PCP was also 
reported by Howard-Butcher (University of 
California, Los Angeles) and Johnson 
(University of Texas, Galveston), to 
increase dopamine release in similar assays 
but at higher doses. 
M. E. and A. T. Eldefrawi (Maryland) 
pointed out that [SHIPCP binds to allosteric 
sites on the ACh receptor of the torpedo 
electric organ and to proteins in crayfish 
abdominal muscle membranes. The latter 
binding is particularly sensitive to divalent 
cations, which inhibit Ca*+ channels. The 
rank-order of several PCP analogs in dis- 
placing [SH]PCP binding to crayfish protein 
correlates better with their inhibition of 
[8H]PCP binding to rat brain than to the tor- 
pedo ACh receptor. Although PCP actions 
on the Caz+ channel are implicated, 
Albuquerque of the same University could 
find no direct effects of PCP on the Ca’+ 
channel of the frog neuromuscular junc- 
tion. 
Due to illness, neither Maayani nor 
Weinstein (Mount Sinai) was able to 
attend the seminar. The abstract of their 
paper covered the discriminant strut 
ture-activity relations of PCP and its 
derivatives, as well as the multiple phar- 
macological actions of PCP in which its 
actions on the muscarinic cholinergic recep 
tor as well as on K+ channels in cardiac 
muscle were studied. In spite of the absence 
of these investigators, the round table dis. 
cussion chaired by Vincent brought out 
some heated discussion, in which the 
majority felt that the evidence for a distinct 
PCP receptor was considerable, and that the 
problem of the rapid filtration assay raised 
by the Weinstein group had now been 
resolved. All lamented the lack of a specific 
PCP antagonist and its need in further PCP 
receptor studies. 
The biotransformation of the piperidine 
ring of PCP was described by Cho and 
Kammerer and colleagues (University of 
California, Los Angeles). They used rat 
and rabbit 9 000 x g liver supematant to 
show the conversion of PCP to (l- 
phenylcyclohexyl)-1,2,3,4tetrahydropyti- 
dine, a possible decomposition product of 
the corresponding carbinolamine. The N- 
oxide of PCP was not an important inter- 
mediate. Their data indicated that 5-[N- 
(1 ‘-phenylcyclohexylkunino] pentanoic 
acid and N- (5hydroxypentyl> l-phenyl- 
cyclohexylamine are formed from the car- 
binolamine of PCP or its open ring form, 
through oxidation or reduction by soluble 
liver enzymes. Kalir (Tel-Aviv) and Trevor 
(University of California, San Francisco) 
and colleagues reported on the formation of 
an iminium ion of PCP. The metabolically 
dependent covalent binding of [sH]PCP to 
microsomal proteins was inhibited by 
cyanide ions, suggesting that the interaction 
of their iminium derivative of PCP could 
explain the long term, and irreversible bind- 
ing of PCP to cellular proteins. Holsztynska 
and Domino (Michigan) described a new 
major route of phencyclidine biotransfor- 
mation via hydroxylation at the 3 position 
of the cyclohexyl ring and subsequent for- 
mation of dihydroxylated derivatives, 3,4- 
dihydroxycyclo PCP and 3-hydmxycyclo- 
4-hydroxy-pip PCP in mouse, monkey and 
human. This pathway is deficient in certain 
inbred strains of mice and is completely 
undetectable in the rabbit. In general 
alicyclic hydroxylations occur preferen- 
tially over aromatic hydroxylations. The 3- 
and Cpositions on the cyclohexyl ring and 
the Qposition on the piperidine are prefer- 
red sites of PCP oxidation. Hydroxylation 
of the aromatic ring of PCP, if any, occurs 
only in trace amounts. Each hydroxylation 
of PCP on the alicyclic ring is probably 
mediated via a different form of cyto- 
chrome P450, as suggested by differential 
abundance and inducibility of each path- 
way in various mouse strains. On the basis 
of experiments with inbred strains of mice, 
it was concluded that the hydroxylations of 
PCP on alicyclic rings are mediated by 
cytochrome P450 forms different from 
those associated with aryl hydrocarbon 
hydroxylase activity. Trevor and his col- 
leagues (University of California, San 
Francisco) reported on the remarkable 
stereoselective biotransformation of the 
enantiomers of ketamine by the liver of rats 
and human heart transplant donors. Marked 
stereoselectivity was observed in alicyclic 
ring hydroxylation in rat hepatic micro- 
somes in contrast to that from humans. The 
major hydroxylated metabolites formed 
from both ketamine enantiomers by human 
liver microsomes were Qhydroxyketamine 
and 6hydroxynorketamine. 
An overview of the human behavioral 
psychopharmacology of the arylcyclo 
hexylamines was provided by Gallant 
(Tulane). PCP is a positive reinforcer in 
animals and, presumably, in man because it 
is abused extensively. A rather high inci- 
dence of PCP intoxication was observed in 
patients treated in the New Orleans Charity 
Hospital Emergency Room. Marked and 
confusing mental and neurologic sympto 
matology was observed in these patients. 
Gallant stressed the fact that the lipophilic 
nature of PCP and the prolonged clinical 
course of psychotic behavior in some 
patients may be associated with a slow rate 
of PCP excretion in the urine. For example, 
human urines can be positive for PCP as 
long as 30 days after the last exposure, with 
positive urines averaging 2 weeks after the 
last use of PCP. Aniline, Pitts and asscr 
ciates (University of Southern California) 
stressed the serious nature of PCP abuse in 
patients at Los Angeles County Hospital. 
They emphasized that epidemiological 
studies on the prevalence of PCP abuse 
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must be based upon highly sensitive and 
specific methods of PCP analyses in blood 
or urine, especially using modem gas 
chromatographic-mass spectrometric 
methods for detecting not only PCP but also 
its related congeners of abuse. Lack of suit- 
able and sophisticated analytical methods to 
measure these substances may lead to false 
assumptions in surveys reporting, for in- 
stance, decreased use of PCP, while street 
use may involve smaller dosage of PCP and 
a shift to the use of its congeners. 
While PCP is a major drug of abuse in the 
USA, Ingold (Centre Medical Marmottan) 
pointed out that PCP is not abused in France 
at this time. He suggested that its abuse in 
the USA is due to its general availability. 
Why do people use PCP? Ingold suggested 
its unique pharmacological properties of 
euphoria, amnesia and anesthesia; group 
pressure to accept a risk, and PCP negative, 
as well as positive reinforcing properties to 
induce a change of mental state, are all 
involved. PCP induces a unique state of dis- 
tortion of body image, akin to a phantom 
limb syndrome. 
Braude (US National Institute on Drug 
Abuse) provided an overview of the NIDA 
biomedical program on PCP and metabo 
lites. Due to the epidemic of PCP abuse in 
the USA, beginning in 1979 NIDA funded 
about 40 projects and contracts on PCP in 
relation to other drugs of abuse, of which 17 
projects were on PCP alone. Reduced 
availability of funds and reassessment of 
NIDA priorities will undoubtedly bring 
PCP research to a lower level in the future. 
In view of the scientific and public interest 
in PCP, the majority of participants felt this 
was most regrettable. 
Balster and Wessinger (Virginia) 
reviewed their extensive research on the 
CNS depressant effects of PCP. Although 
PCP and other arylcyclohexylamines pro- 
duce a unique type of general anesthesia, 
PCP has many pharmacological and 
behavioral effects similar to typical CNS 
depressants, such as the barbiturates. These 
include the phenomena of tolerance and 
dependence. PCP also markedly enhances 
the depressant effects of barbiturates. 
Mayersohn and associates (Arizona) 
reported on PCP disposition kinetics in 
dogs. They developed a radioimmunoassay 
for PCP, and a capillary column gas 
chromatographic method using nitrogen 
detection for a number of its metabolites. 
In dogs, PCP has an extremely large vol- 
ume of distribution indicating extensive dis- 
tribution to tissues. Systemic clearance of 
PCP was large, and approached the value of 
hepatic blood flow. PCP is poorly bound to 
serum proteins with dependence on pH. 
Binding of PCP increases with pH. This 
raises an interesting question as to what are 
the consequences of extensive acidification 
techniques during PCP intoxication. 
Only 80% of the total dose of [SHIPCP 
could be accounted for, based on urinary (c. 
60%) and fecal (c. 20%) excretion. About 
1% of the dose of PCP is excreted in the dog 
as free PCP in the urine, with various 
metabolites, especially the aminopentanoic 
acid derivative (14.7%). Woods 
(Michigan) reported on drug modification 
of PCP discriminative performance in 
pigeons and rhesus monkeys. The data 
indicate a unique nature of PCP discrimina- 
tive cues, which are shared by related aryl- 
cyclohe.xylamines as well as certain benzo 
motphans and homobenzomorphans. 
Haloperidol, diazepam and l-phenyliso- 
propyladenosine, in doses sufficient to alter 
performance, failed to alter the discrimina 
tive control of PCP. Important species dif- 
ferences to different drug classes were also 
noted. 
Shannon (US National Institute on Drug 
Abuse) reported on the structure-activity 
relationships for producing arylcyclohexyl- 
aminelike behavioral effects in rats. In 
contrast with other investigators who use 
food reinforcement in discriminative 
stimulus studies, he used shock avoidance 
in rats. This facilitated the use of larger 
doses of these agents in determining their 
behavioral effects. Systematic strut 
tune-activity studies allowed Shannon and 
his colleagues to define the properties of the 
PCP receptor, including an anionic site 
which binds the protonated nitrogen, two 
opposing n aromatic sites and an inter- 
mediate lipophilic area. 
Stiller and colleagues (Pittsburgh) 
reported on the developmental aspects of 
the human clinical pharmacokinetics of 
ketamine. Their data, using cardiac 
patients, were surprisingly consistent with 
other reports in the literature in which 
ketamine has a short t 112 o-phase of about 10 
min and a much longer t rn pphase of about 
120 min. Some unique data in infants, chil- 
dren and pregnant females during labor 
were also described. Ketamine t I/Z Pphase 
was faster (55 min) in children (l-5 yr) and 
slower (185 mm) in infants (2-10 m) than 
adults. The hemodilution effects of cardiac 
bypass (CBP) altered the &phase in all 
patients, but resumed a log-linear concen- 
tration curve after CBP was concluded. 
Ketamine plasma protein binding levels 
were elevated in all patients except in the 
cord blood, w,here they were l/3 to l/2 
those of the mother. These investigators 
also showed that increasing the blood pH 
increased ketamine binding, as is true for 
PCP. Emory University supplied some of 
the patient samples. 
Albuquerque and associates reported on 
the ability to differentiate behaviorally 
active from inactive PCP analogues based 
on the interaction of the compounds with 
ionic channels of electrically excitable 
membranes and cholinergic receptors. An 
important correlation was made between 
the ability of PCP and its derivatives to 
block K+- and Na+-channel inactivation 
rather than affect the recognition sites of 
‘cholinergic receptors. 
Palmer, Hoffer and associates (Col- 
orado) described the remarkable properties 
of PCP and related derivatives on the 
release of norepinephrine (NE) from the rat 
cerebellum and hippocampus. These inves 
tigators used electrophysiological methods, 
together with micropressure ejection from 
multibanelled micropipettes, to show that 
PCP mimicked the actions of NE on single 
unit activity, with ketamine being about l/5 
as potent. PCP no longer exerted its de 
pressant actions on cerebellar Purkinje cells 
following lesions of the NE innervation to 
cerebellum with 6-OH dopamine, intenup 
tion of presynaptic NE release by local 
Mg.+ applications, or NE depletion by, 
reserpine administration. These data sug- 
gest a presynaptic effect of PCP on NE 
release. The effect of PCP on hippocampal 
neurons was more complex, but consistent 
with a presynaptic mechanism of action at 
monoamine synapses. Higher doses caused 
local anesthetic effects in both brain areas. 
The expected stereospecific potency differ- 
ences of PCP analogues were also 
described. 
Lodge and associates (Royal Veterinary 
College, London) pointed out that the aryl- 
cyclohexylamines selectively reduce exci- 
tation of cat central neurons by aspartate 
like amino acids. They used the technique 
of microiontophoresis and studied 
ketamine in particular. Ketamine reversibly 
reduced the excitation of spinal cord 
neurons by N-methylaspartate to a greater 
extent than that of either kainate or quis- 
qualate. The (+ ~enantiomer of ketamine 
was 3X as potent as its (-)-isomer as an 
N-methylaspattate antagonist, and only 1 
to 1.5x as potent as an ACh antagonist. 
Ketamine had no effect on GABA- 
mediated transmission in contrast to bar- 
biturates which potentiated it. 
Howard-Butcher showed that there was 
an inn-viva release of dopamine (DA) in the 
cat caudate nucleus after PCP administra 
tion using the technique of cyclic vol- 
tametry. In addition she showed that PCP 
affected ACh turnover consistently with its 
effects on DA release in the striatum. 
Murray (Washington State University) and 
his colleagues (NIMH at St. Elizabeth’s 
Hospital) compared the effects of PCP with 
those of other psychoactive drugs on 
cholinergic dynamics in the rat brain. Sub 
anesthetic doses of PCP and ketamine 
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resent the a-opioid receptor. Two other 
sites of high affinity for ethytketccyc 
lazocine not affected by PCP may represent 
K-opioid or benzomorphan sites. 
Kamenka, Geneste and coworkers demon- 
strated by ‘YLNMR spectroscopy that the 
stereoisomers in the 4-aryl-Qpiperidino- l- 
phenethyl cyclohexanol series of hydro- 
chloride salts are easily distinguishable by 
the chemical shifts of the methylene group 
OL to the cyclohexane ring. 
Rondoin, Baldy-Moulinier and asso- 
ciates (Montpelher) have mcorded cortical 
and hippocampal EEG activity in chronic 
rats. PCP (2-5 mg kg-‘), or its active 
analogues, produced awake EEG activity 
associated with locomotor stimulation dur- 
ing the fit hour following i.p. injection. 
Slow wave sleep and, finally, paradoxical 
sleep reappeared later. No changes in 
&activity were observed. Levine (Univer- 
sity of California, Los Angeles) reported 
that chronic PCP treatment in doses of l-2 
mg kg-’ produced marked behavioral 
effects in developing kittens. He compared 
the effects of chronic low doses of PCP with 
single larger doses of PCP, two of its 
metabolites, I-phenylcyclohexylamine, N- 
(5 - hydroxypentyl) - 1 - phenylcyclohexyl- 
amine, and the PCP analog N,N-diethyl- 
I-cyclohexylamine. The most intense PCP 
induced motor responses in kittens 30-50 
days of age, consisted of waxy rigidity. The 
N,N-diethyl analog produced less intense 
effects. The two PCP metabolites were less 
active, with the alcohol derivative being the 
least potent. 
Lozovsky, Kopin and associates (US 
National Institutes of Health) reported that 
PCP caused a rapid dosedependent sup 
pression of plasma prolactin in rats. Toler- 
ance to this effect was observed following 
daily PCP for 28 days. They also showed 
that chronic PCP caused an 18% decrease 
in the B, for [8H]spiperone bmding with 
no change in the KD. Thus, a decrease in 
DA receptors might be responsible for the 
observed tolerance to the acute suppressive 
effect of PCP on plasma prolactin. How- 
ever, there was no tolerance to the 
locomotor stimulant effects following 28 
days of PCP administration in rats.. The 
(+&isomer of 1-( I-phenylcyclohexylb 
3-methylpiperidine was more potent in 
reducing plasma prolactin than its (- )- 
isomer. Their study suggested a PCP agon 
ist action on the DA system to which toler- 
ance can develop, but also a more complex 
effect on locomotor activity. 
It was concluded after four days of inten 
sive presentations and discussions that PCP 
and related arylcyclohexylamines are a 
very rich and fertile subject of research that 
can lead to a better understanding of 
neurobiology, and possibly new therapeu- 
increased ACh turnover in the neocortex 
and diencephalon, but had no effect on 
striatal and hippocampal ACh. This reg- 
ional brain pattern of ACh turnover induced 
by PCP was similar to that of cocaine, but 
was completely different from other classes 
of centrally acting drugs. 
Johnson reported that PCP affects DA 
and ACh release from rat striatal slices in 
vitro. PCP increased the spontaneous 
release of DA but had no effect on K+ 
stimulated [8H]DA release. His results sug- 
gest that PCP releases [SH]DA in a manner 
similar to nonamphetamine stimulants. 
PCP can release both stored and newly 
synthesized DA, which serves to down reg- 
ulate DA synthesis. At similar concentra- 
tions (3-30 pM) PCP inhibited potassium 
stimulated release of [8H]ACh, while 
atropine had no effect. Oxotremorine, a 
muscarinic cholinergic agonist, also inhi- 
bited [sH]ACh release and in combination 
with PCP the effect was additive, suggest- 
ing that the atropinelike properties of PCP 
ate unimportant in this paradigm. The 
(+ )-enantiomer of SKF 10047 but not the 
(- ~enantiomer also inhibited [SH]ACh 
release. This effect was blocked by 
haloperidol, just as with PCP. Hence, PCP 
and (+ >SKF 10047 may stimulate DA 
release via a PCP/o-receptor action. 
Castellani (Wichita) reported on the 
complex role of dopaminergic, cholinergic 
and opioid agonists and antagonists on vari- 
ous aspects of PCP induced behavior in 
rats. His data were consistent with PCP 
induced release of DA and its partial block- 
ade by haloperidol in both rat and man. 
None of the transmitter agonists or antagon 
ists alone reversed all of the complex 
behavioral effects of PCP, because all three 
brain transmitters seemed to be involved. 
Browne and Welch (Pfizer) added adeno 
sine to the list of putative nemotmnsmitters 
involved with PCP effects. They obtained 
data in rats showing that various adenosine 
agonists completely antagonized the dis 
criminative stimulus effects of PCP in vivo 
and blocked the high, but not the low, affii- 
ity receptor of [SH]N&cyclohexyladeno 
sine in vitro. Nabeshima and Kameyama 
(Meijo) studied the actions of acute and 
chronic PCP administration on Met- 
enkephabn in the mouse brain. A complex 
picture was produced by PCP, in which 
there. was a lowering of Met-enkephalin in 
the medulla and midbrain but no change in 
the striatum, hippocampus and neocottex. 
After development of tolerance to PCP, an 
increase in Met-enkephalin levels was 
observed in the striatum. However, during 
morphine withdrawal in PCP tolerant mice, 
the increase in Met-enkephalin levels 
returned close to the control levels. These 
investigators also reported important sex 
differences of PCP in rats. Female rats were 
more sensitive to the diverse effects of PCP 
than males. The enhanced sensitivity of 
females compared with males was related 
to a higher brain content of PCP and more 
prolonged brain and plasma half-lives in the 
females. The content of hepatic micro 
somal cytochrome P450 was also found to 
be lower in the female rats. 
Fukuda and Domino (Michigan) corn 
pared the EEG and gross behavioral effects 
of various dissociative, general and local 
anesthetics in Macuca mulutta. They con- 
cluded that PCP, ketamine, dexoxadrol and 
dextrorphan had similar EEG and gross 
behavioral effects in contrast to the other 
centrally active agents studied. Their fmd- 
ings are consistent with the data obtained 
from stimulus discrimination and PCP 
receptor binding studies. 
Vaupel (US National Institute on Drug 
Abuse) reported on the effects of PCP in the 
chronic spinal dog. The pharmacology of 
PCP, its similarity to SKF 10047 and the 
profiles of eight PCP analogues abused by 
man were studied. He concluded that the 
chronic spinal dog was an excellent model 
in which to study PCP derivatives and 
obtain their behavioral, neurologic and 
physiologic profiles. The structure-activity 
relationships of various PCP derivatives 
were in the expected direction, with PCP 
and SKF 10047 showing very similar 
pharmacological profiles. Von Voigtlander 
and Tang (Upjohn) reported on an exten- 
sive search for PCP antagonists. Although 
no specific antagonists were found, prazo 
sin and clonidine were noted to block a 
number of the effects of PCP in various 
behavioral studies. This suggests an import- 
ant role for the a-adrenergic system in the ’ 
mediation of some of the actions of PCP. 
Quirion and Pert (US National Institute of 
Mental Health) reported on the histochemi- 
cal localization of PCP receptors in the rat 
brain. PCP binding was especially high in 
the hippocampus and neocortex. They also 
showed that D&receptors, as measured by 
labelled spiperone, decreased with chronic 
PCP administration in a manner consistent 
with PCP induced DA release or blockade 
of DA uptake. Especially exciting was their 
report of the isolation of a peptide substance 
of small molecular weight which was a 
potent endogenous ligand of the PCP recep 
tor. They named this peptide ‘angeldus 
tine’. The finding of endogenous peptides 
that displace PCP from its receptor was also 
reported by Vincent and associates and the 
zukins. 
Morre and associates (Sanofi) used 
guinea-pig brain membranes,to show that 
PCP displaces [8H]ethylketocyclazocine 
from its low affinity binding site. This site, 
which is insensitive to naloxone, may rep 
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tic agents, particularly in the form of 
ultrashort acting anesthetics and analgesics 
with less respiratory depression. Such short 
acting agents would probably be less 
abused than longer acting compounds like 
PCP itself, with metabolites that irrevers 
ibly bind to proteins. The ultimate question 
still remaining unanswered after the meet- 
ing was why are there PCP receptors and 
related endogenous peptide ligands in the 
brain? For what purpose? Are-they there to 
produce a dissociated mental state follow- 
ing severe trauma or stress? 
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Key developments in pharmacology 
Conformation-activity study of 
4=phenylpiperidine analgesics 
In the light of the original hypothesis’ that 
analgesic 4phenylpiperidines should have 
their phenyl ring in an axial position on the 
piperidine ring, in analogy with the rigid 
polycyclic analgesics such as morphine, it 
is rather puzzling to note that over the years 
an impressive amount of experimental data 
has accumulated which shows, almost 
without exception, that the phenyl ring is in 
an equatorial position. In fact, X-my cry- 
stallographic analysis, nuclear magnetic 
resonance data and quantum chemical cal- 
culations indicate that compounds structur- 
ally related to pethidine and prodines, have 
their phenyl rings in an equatorial position 
on the piperidine ring. 
The fact that the various diastereoiscr 
mers of prodines and prodine-like anal- 
gesics show marked enantiomeric and 
diastereoisomeric potency differences, 
make these compounds extremely valuable 
for gaining a better understanding of recep 
tor and receptor-induced events. As the 
question of axial v. equatorial phenyl has 
not yet been satisfactorily settled, 
Froimowitz’ addressed the problem of the 
energy differences between phenyl equator- 
ial and phenyl axial conformers in various 
Cphenylpiperidine analgesics. 
The conformational energy of pethidine 
I, ketobemidone II, cY-prodine III, 
fi-prodine IV and 1,3,4 - trimethyl - 4 - 
phenylpipetidines V was studied using the 
MM2 (Molecular Mechanics Il) program 
developed by Alhnger and coworker?. The 
MM2 program is based on forcefield cal- 
culations, and therefore offers the distinct 
advantage of speed of calculation over even 
the fastest semi-empirical quantum chemi- 
cal calculation, such as PCILO (Perturba- 
tive Configuration Interaction using Local- 
ized Orbitals). Owing to its speed, this 
method of calculating empirical potential 
functions allows the user to minimize a 
structure with respect to all internal co- 
ordinates (bond lengths, bond angles and 
torsion angles). 
Phenyl equatorial conformations were 
found to be preferred for I and II over the 
phenyl axial conformation by only 0.6 and 
0.7 Kcal mole-’ respectively. The energy 
differences between the phenyl equatorial 
and axial conformers were calculated to be. 
1.9, 2.8 and 3.4 Kcal mole-’ in favour of 
the phenyl equatorial conformers for 
3-demethylprodine, (Y- and Pprodine 
(III, IV) mspectively. A phenyl axial con 
former was calculated to be preferred by 
0.7 Kcal mole-’ for the 3-demethyl deriva- 
tive of V whereas the phenyl equatorial 
conformers were preferred by 1.3 and 3.3 
Kcal mole-’ for the OL- and /3-compounds 
W). 
The results clearly show that the equilib- 
rium distribution of phenyl equatoriaLaxial 
is quite variable, and depends on the nature 
of the substituent on the Cposition and the 




The relatively small energy difference 
between the axial and equatorial phenyl 
conformers of I and II suggests that in solu- 
tion there should be an appreciable popula- 
tion of phenyl axial conformers present. 
This would make the structure-activity 
relationships of I and II more similar to the 
rigid Cphenyl axial morphmomimetics, 
such as morphine, where the introduction 
of a meta hydroxy group is known to en- 
hance potency. A similar effect of the meta 
hydroxy group is known for I and II. The 
fact that a meta hydroxy group has a detri- 
mental effect on the analgesic activity of the 
prodines is in accord with the present calcu- 
lations indicating that the phenyl axial con- 
formation populations are virtually non- 
existent. It is noted, however, that I and II 
are still different from the rigid Cphenyl 
axial morphinomimetics, since N-ally1 
groups do not convert them into antagon- 
ists. 
Whether the phenyl axial conformation 
is intimately connected with the presence of 
a meta hydroxy group is, however, still not 
settled, owing to the observation that 
phenylmorphans contain a meta- 
hydroxylated phenyl in a fixed equatorial 
position. 
The present study of Froimowitz clearly 
suggests that a 3-methyl substituent on the 
piperidine ring strongly governs the prefer- 
yOCP5 I)COC2H5 
